Logo image of ASPI

ASP ISOTOPES INC (ASPI) Stock Fundamental Analysis

NASDAQ:ASPI - Nasdaq - US00218A1051 - Common Stock - Currency: USD

8.08  +0.28 (+3.59%)

Fundamental Rating

3

Overall ASPI gets a fundamental rating of 3 out of 10. We evaluated ASPI against 85 industry peers in the Chemicals industry. While ASPI seems to be doing ok healthwise, there are quite some concerns on its profitability. ASPI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ASPI has reported negative net income.
ASPI had a negative operating cash flow in the past year.
ASPI Yearly Net Income VS EBIT VS OCF VS FCFASPI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of ASPI (-37.22%) is worse than 91.76% of its industry peers.
With a Return On Equity value of -73.31%, ASPI is not doing good in the industry: 85.88% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -37.22%
ROE -73.31%
ROIC N/A
ROA(3y)-45.32%
ROA(5y)N/A
ROE(3y)-74.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASPI Yearly ROA, ROE, ROICASPI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

ASPI has a better Gross Margin (38.60%) than 78.82% of its industry peers.
The Profit Margin and Operating Margin are not available for ASPI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASPI Yearly Profit, Operating, Gross MarginsASPI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

ASPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASPI has more shares outstanding
ASPI has a worse debt/assets ratio than last year.
ASPI Yearly Shares OutstandingASPI Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
ASPI Yearly Total Debt VS Total AssetsASPI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ASPI has an Altman-Z score of 6.30. This indicates that ASPI is financially healthy and has little risk of bankruptcy at the moment.
ASPI has a better Altman-Z score (6.30) than 96.47% of its industry peers.
ASPI has a Debt/Equity ratio of 0.76. This is a neutral value indicating ASPI is somewhat dependend on debt financing.
ASPI has a Debt to Equity ratio (0.76) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF N/A
Altman-Z 6.3
ROIC/WACCN/A
WACC9.05%
ASPI Yearly LT Debt VS Equity VS FCFASPI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

ASPI has a Current Ratio of 9.31. This indicates that ASPI is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ASPI (9.31) is better than 97.65% of its industry peers.
A Quick Ratio of 9.31 indicates that ASPI has no problem at all paying its short term obligations.
ASPI's Quick ratio of 9.31 is amongst the best of the industry. ASPI outperforms 97.65% of its industry peers.
Industry RankSector Rank
Current Ratio 9.31
Quick Ratio 9.31
ASPI Yearly Current Assets VS Current LiabilitesASPI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ASPI have decreased strongly by -30.23% in the last year.
ASPI shows a strong growth in Revenue. In the last year, the Revenue has grown by 857.11%.
EPS 1Y (TTM)-30.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.8%
Revenue 1Y (TTM)857.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%175.75%

3.2 Future

ASPI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.69% yearly.
Based on estimates for the next years, ASPI will show a very strong growth in Revenue. The Revenue will grow by 109.96% on average per year.
EPS Next Y71.93%
EPS Next 2Y44.49%
EPS Next 3Y32.97%
EPS Next 5Y26.69%
Revenue Next Year682.93%
Revenue Next 2Y288.81%
Revenue Next 3Y183.67%
Revenue Next 5Y109.96%

3.3 Evolution

ASPI Yearly Revenue VS EstimatesASPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
ASPI Yearly EPS VS EstimatesASPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ASPI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ASPI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASPI Price Earnings VS Forward Price EarningsASPI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASPI Per share dataASPI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

4.3 Compensation for Growth

ASPI's earnings are expected to grow with 32.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.49%
EPS Next 3Y32.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ASPI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASP ISOTOPES INC

NASDAQ:ASPI (5/23/2025, 11:44:07 AM)

8.08

+0.28 (+3.59%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)05-12 2025-05-12
Earnings (Next)N/A N/A
Inst Owners44.73%
Inst Owner Change-1.09%
Ins Owners18.58%
Ins Owner Change10.87%
Market Cap582.33M
Analysts82.5
Price Target6.63 (-17.95%)
Short Float %32.44%
Short Ratio9.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-36.17%
Min EPS beat(2)-41.61%
Max EPS beat(2)-30.72%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.79%
Min Revenue beat(2)-3.12%
Max Revenue beat(2)-2.45%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-66.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-74.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 140.51
P/FCF N/A
P/OCF N/A
P/B 12.16
P/tB 13.02
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.06
BVpS0.66
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.22%
ROE -73.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.6%
FCFM N/A
ROA(3y)-45.32%
ROA(5y)N/A
ROE(3y)-74.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2412.47%
Cap/Sales 274.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.31
Quick Ratio 9.31
Altman-Z 6.3
F-Score5
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.8%
EPS Next Y71.93%
EPS Next 2Y44.49%
EPS Next 3Y32.97%
EPS Next 5Y26.69%
Revenue 1Y (TTM)857.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%175.75%
Revenue Next Year682.93%
Revenue Next 2Y288.81%
Revenue Next 3Y183.67%
Revenue Next 5Y109.96%
EBIT growth 1Y-64.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-262.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-208.47%
OCF growth 3YN/A
OCF growth 5YN/A